DataSheet_3_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

“…Knockdown of ALKBH5 increased global m⁶A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”

DataSheet_6_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

“…Knockdown of ALKBH5 increased global m⁶A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”

DataSheet_1_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

“…Knockdown of ALKBH5 increased global m⁶A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”

DataSheet_2_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

“…Knockdown of ALKBH5 increased global m⁶A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”

DataSheet_7_RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.zip by Xiangli Liu (507857)

“…Knockdown of ALKBH5 increased global m⁶A level, and also increased E-cadherin, decreased stem hallmarkers, Nanog and Oct4, and inhibited stemness of CSCs. …”

Inhibition of PKA by siRNA increased cell proliferation and decreases apoptosis in endothelial cells under high glucose treatment. by Zhaoyun Zhang (118032)

“…<p>Cells were transfected with siRNA and then treated with 5.6 mM glucose or 25 mM glucose for 72 hours: A: siRNA enhanced cell proliferation under high glucose conditions B: siRNA decreased apoptosis under high glucose conditions. *, p<0.05 compared with 5.6 mM condition. n = 6.…”

Knockdown of OAMB or 5-HT_1A in IPCs resulted in opposite phenotypes in a capillary feeding assay (CAFE). by Jiangnan Luo (218899)

“…<p><b>A</b> Diminishing 5-HT_1A in IPCs (<i>Dilp2</i>-Gal4><i>5-HT_1A</i>-RNAi) significantly decreases food intake only during day 2. …”

Decreasing <i>EloC</i> expression suppresses ectopic veins induced by <i>blistered</i> loss-of-function. by Julien Rougeot (131135)

DataSheet1_Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.DOCX by Chuchu Zhang (2562154)

“…</p><p>Results: Anti-IL-5 therapy was associated with a decrease in acute exacerbation rate (RR 0.89; 95% CI 0.84 to 0.95, I² = 0%) and the severe adverse events (RR 0.90; 95% CI 0.84 to 0.97, I² = 0%). …”

Increased survival and decreased bacterial sepsis-associated tissue damage of mice with T-cell targeted deletion of HIF-1α. by Manfred Thiel (310810)

24 hour delayed 2-MeSADP treatment decreases the size of cortical lesions induced by single vessel photothrombosis. by Wei Zheng (25452)

Blocking TPL2 activity decreases cytokine synthesis driven by PsaDM stimulation of BEAS-2B AECs. by Guy Martel (391836)

Swift-like roughness decreases drag below Reynolds 24,000 and increases drag beyond, during straight glides. by David Lentink (588652)

Image 5_Neutrophil proteins as potential biomarkers for a sputum-based tuberculosis screening test.tif by Mark Chambers (1845670)

Image_5_MiR-27a-3p and miR-30b-5p inhibited-vitamin D receptor involved in the progression of tuberculosis.TIFF by Min Xiao (320004)

“…Two candidate miRNAs, miR-27a-3p, and miR-30b-5p, were identified by a high-throughput sequencing screen and validated by qRT–PCR assays. …”

Treatment with C2IN-C3lim decreases the resorption of synthetic calcium phosphate surfaces by already differentiated osteoclasts. by Andrea Tautzenberger (502772)

Flowchart of in- and exclusion. by Patrick Ristau (13794436)

Subjects:

Dataset definition of minimal underlying data. by Patrick Ristau (13794436)

Subjects:

Survival at hospital discharge. by Patrick Ristau (13794436)

Subjects:

Baseline characteristics, initial management, and outcome of OHCA. by Patrick Ristau (13794436)

Subjects: